Page 9 - Dr Reddys
Sun Pharma, Dr Reddy's, Aurobindo recall products in the US market
Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling products in the US market, the world's largest market for pharmaceutical products, for various reasons
 "Sun Pharma, Dr Reddy's, Aurobindo recall products in the US market")
Bull Spread strategy on Dr Reddy's Labs by Nandish Shah of HDFC Securities
The stock price has broken out on the daily chart where it closed above 200-day EMA with higher volumes
 "Bull Spread strategy on Dr Reddy's Labs by Nandish Shah of HDFC Securities")
Stocks to watch: Nureca, Max Fin, Axis Bank, DRL, Dredging Corp, Affle
Wipro announced the appointment of Rene Mulder as Country Head and Managing Director of its Switzerland operations
 "Stocks to watch: Nureca, Max Fin, Axis Bank, DRL, Dredging Corp, Affle")
Dr Reddy's launches stomach, esophagus problems treatment drug in US
The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA)
 "Dr Reddy's launches stomach, esophagus problems treatment drug in US")
Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in US
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA)
 "Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in US")
Dr Reddys falls 10% in 2 days, hits over 4-month low post Q3 results
The company said the profits were impacted due to trigger based impairment charge taken on a few acquired products including gNuvaring
 "Dr Reddys falls 10% in 2 days, hits over 4-month low post Q3 results")
Dr Reddy's posts Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore
Dr Reddy's Laboratories on Friday reported a consolidated net profit of Rs 20 crore for the October to December quarter as against a consolidated net loss of Rs 570 crore in the year-ago period.Not accounting for impairment cost, the company's net profit in the quarter would have been at Rs 882 crore, it said.The company's consolidated revenues grew 12 per cent year-on-year to Rs 4,930 crore.There were significant changes to the market conditions for certain of the products fanning part of company's global generics and proprietary products segments, said the company."We continued with our growth momentum while maintaining EBITDA margins. We are progressing well on phase three clinical trials for Sputnik V vaccine in India," said Co-Chairman and Managing Director G V Prasad.The company's revenues in India increased by 26 per cent year-on-year to Rs 959 crore in Q3 FY21. In North America, the sales rose 9 per cent to Rs 1,739 crore.
Dr Reddy's to acquire select brands from Glenmark in Russia, Ukraine
Dr Reddy's Laboratories on Saturday said it had inked a pact with Glenmark Pharmaceuticals to acquire its select anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan
Weekly stock picks by Religare Broking: Buy Aurobindo Pharma, Marico
The chart pattern and positioning of oscillators are pointing towards a sharp up move in Aurobindo Pharma in the near future
 "Weekly stock picks by Religare Broking: Buy Aurobindo Pharma, Marico")
A brief history of Indian companies' tryst with class action suits
Companies ranging from IT to pharmaceuticals have been dragged to courts
 "A brief history of Indian companies' tryst with class action suits")
Sensex ends 134 pts lower, Nifty settles at 11,505; Nifty Pharma jumps 5%
All that happened in the markets today
 "Sensex ends 134 pts lower, Nifty settles at 11,505; Nifty Pharma jumps 5%")
BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs
Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma, and Hikal hit their respective 52-week highs on the BSE
 "BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs")
Russia ropes in Dr Reddy's to sell 100 mn Covid-19 vaccine doses; stk up 4%
Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, Dr Reddy's said in a statement
New launches, patents: Multiple catalysts for Dr Reddy's US business
The ongoing pace of product launches in the US should lead to stronger growth after a good Q1, say analysts
 "New launches, patents: Multiple catalysts for Dr Reddy's US business")
Cipla tweaks management structure to mobilise second level of executives
Do these changes augur well for the future business growth plans? Analysts think so
 "Cipla tweaks management structure to mobilise second level of executives")
TCS, Infosys, and Dr Reddy's shares hit fresh record highs
Dr Reddy's rallied 5 per cent to Rs 4,524 today, surging 12 per cent in the past two trading days after the company reported a strong operational performance in Q1FY21.
 "TCS, Infosys, and Dr Reddy's shares hit fresh record highs")
India's coronavirus drug market set for price war as firms ready launches
Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.
 "India's coronavirus drug market set for price war as firms ready launches")
Covid-19 crisis: Made-in-India remdesivir may come by end of June
Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.
 "Covid-19 crisis: Made-in-India remdesivir may come by end of June")
Revised Wockhardt deal boosts prospects of Dr Reddy's India business
The company, according to its new strategy, is focusing on growing its India-based branded products
 "Revised Wockhardt deal boosts prospects of Dr Reddy's India business")
Dr Reddy's Q4 PBT up 22% at Rs 714 cr on buoyant US, European business
The company has registered 10% growth in revenues at Rs 4,431.8 cr for the quarter under review from Rs 4,016.6 cr in the year-ago period
 "Dr Reddy's Q4 PBT up 22% at Rs 714 cr on buoyant US, European business")